References

• American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders: DSM-5-TR (5th ed., text rev.). American Psychiatric Association Publishing.
• Carlson, G. A., Potegal, M., Margulies, D., Basile, J., & Gutkovich, Z. (2010). Liquid risperidone in the treatment of rages in psychiatrically hospitalized children with possible bipolar disorder. Bipolar Disorders, 12(2), 205–212. https://doi.org/10.1111/j.1399-5618.2010.00793.x
• Dickstein, D. P., Towbin, K. E., Van Der Veen, J. W., Rich, B. A., Brotman, M. A., Knopf, L., Onelio, L., Pine, D. S., & Leibenluft, E. (2009). Randomized double-blind placebo-controlled trial of lithium in youths with severe mood dysregulation. Journal of Child and Adolescent Psychopharmacology, 19(1), 61–73. https://doi.org/10.1089/cap.2008.044
• Donovan, S. J., Stewart, J. W., Nunes, E. V., Quitkin, F. M., Parides, M., Daniel, W., Susser, E., & Klein, D. F. (2000). Divalproex treatment for youth with explosive temper and mood lability: A double-blind, placebo-controlled crossover design. American Journal of Psychiatry, 157(5), 818–820. https://doi.org/10.1176/appi.ajp.157.5.818
• Kim, S., & Boylan, K. (2016). Effectiveness of antidepressant medications for symptoms of irritability and disruptive behaviors in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 26(8), 694–704. https://doi.org/10.1089/cap.2015.0127
• Krieger, F. V., Pheula, G. F., Coelho, R., Zeni, T., Tramontina, S., Zeni, C. P., & Rohde, L. A. (2011). An open-label trial of risperidone in children and adolescents with severe mood dysregulation. Journal of Child and Adolescent Psychopharmacology, 21(3), 237–243. https://doi.org/10.1089/cap.2010.0123
• Morrow, K., Young, K. A., Spencer, S., Medina, E. S., Marziale, M. A., Sanchez, A., & Bourgeois, J. A. (2020). Utility of oxcarbazepine in the treatment of childhood and adolescent psychiatric symptoms. Proceedings (Baylor University Medical Center), 34(1), 34–39. https://doi.org/10.1080/08998280.2020.1826259
• Perepletchikova, F., Nathanson, D., Axelrod, S. R., Merrill, C., Walker, A., Grossman, Perepletchikova, F., Nathanson, D., Axelrod, S. R., Merrill, C., Walker, A., Grossman, M., Rebeta, J., Scahill, L., Kaufman, J., Flye, B., Mauer, E., & Walkup, J. (2017). Randomized Clinical Trial of Dialectical Behavior Therapy for Preadolescent Children With Disruptive Mood Dysregulation Disorder: Feasibility and Outcomes. Journal of the American Academy of Child and Adolescent Psychiatry, 56(10), 832–840. https://doi.org/10.1016/j.jaac.2017.07.789
• Stoddard, J., Wiggins, J. L., & Wakschlag, L. S. (2021). Editorial: Defining the clinical boundary of disruptive mood dysregulation disorder symptoms in youth. Journal of the American Academy of Child and Adolescent Psychiatry, 60(2), 216–218. https://doi.org/10.1016/j.jaac.2020.12.019
• Tourian, L., LeBoeuf, A., Breton, J. J., Cohen, D., Gignac, M., Labelle, R., Guile, J. M., & Renaud, J. (2015). Treatment options for the cardinal symptoms of disruptive mood dysregulation disorder. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 24(1), 41–54.
• Towbin, K., Vidal-Ribas, P., Brotman, M. A., Pickles, A., Miller, K. V., Kaiser, A., Vitale, A. D., Engel, C., Overman, G. P., Davis, M., Lee, B., McNeil, C., Wheeler, W., Yokum, C. H., Haring, C. T., Roule, A., Wambach, C. G., Sharif-Askary, B., Pine, D. S., Leibenluft, E., & Stringaris, A. (2020). A double-blind randomized placebocontrolled trial of citalopram adjunctive to stimulant medication in youth with chronic severe irritability. Journal of the American Academy of Child and Adolescent Psychiatry, 59(3), 350–361. https://doi.org/10.1016/j.jaac.2019.05.015
• Waxmonsky, J., Pelham, W. E., Gnagy, E., Cummings, M. R., O'Connor, B., Majumdar, A., Verley, J., Hoffman, M. T., Massetti, G. A., Burrows-MacLean, L., Fabiano, G. A., Waschbusch, D. A., Chacko, A., Arnold, F. W., Walker, K. S., Garefino, A. C., & Robb, J. A. (2008). The efficacy and tolerability of methylphenidate and behavior modification in children with attention deficit/hyperactivity disorder and severe mood dysregulation. Journal of Child and Adolescent Psychopharmacology, 18(6), 573–588. https://doi.org/10.1089/cap.2008.065
• Waxmonsky, J. G., Wymbs, F. A., Pariseau, M. E., Belin, P. J., Waschbusch, D. A., Babocsai, L., Fabiano, G. A., Akinnusi, O. O., Haak, J. L., & Pelham, W. E. (2013). A novel group therapy for children with ADHD and severe mood dysregulation. Journal of Attention Disorders, 17(6), 527–541. https://doi.org/10.1177/1087054711433423
• Winters, D. E., Fukui, S., Leibenluft, E., & Hulvershorn, L. A. (2018). Improvements in irritability with open-label methylphenidate treatment in youth with comorbid attention deficit/hyperactivity disorder and disruptive mood dysregulation disorder. Journal of Child and Adolescent Psychopharmacology, 28(5), 298– 305. https://doi.org/10.1089/cap.2017.0124